Table 4

Subgroup analysis of second-line abatacept effectiveness by reasons for treatment failure
Measure Baseline Change from baseline to month 6 Remission at month 6 LDAS at month 6
N Mean (SD) N Mean (95% CI) N Percent (95% CI) N Percent (95% CI)
Primary inefficacy
DAS28 (ESR) 129 5.6 (1.3) 113 −1.5 (−1.7, –1.2) 119 17.6 (10.8, 24.5) 119 29.4 (21.2, 37.6)
DAS28 (CRP) 35 5.2 (1.3) 26 −1.3 (−2.0, –0.7) 32 12.5 (1.0, 24.0) 32 34.4 (17.9, 50.8)
CDAI 140 32.1 (13.1) 129 −13.9 (−16.3, –11.5) 136 2.9 (0.1, 5.8) 136 27.9 (20.4, 35.5)
Secondary inefficacy
DAS28 (ESR) 249 5.6 (1.1) 219 −1.4 (−1.6, –1.2) 240 10.4 (6.6, 14.3) 240 25.0 (19.5, 30.5)
DAS28 (CRP) 74 5.5 (1.3) 55 −1.6 (−2.0, –1.3) 68 20.6 (11.0, 30.2) 68 38.2 (26.7, 49.8)
CDAI 295 32.5 (13.0) 279 −15.4 (−17.1, –13.8) 288 4.2 (1.9, 6.5) 288 29.5 (24.2, 34.8)
Safety and tolerability
DAS28 (ESR) 91 5.5 (1.3) 84 −1.5 (−1.8, –1.2) 98 18.4 (10.7, 26.0) 98 29.6 (20.6, 38.6)
DAS28 (CRP) 27 4.8 (1.4) 22 −1.5 (−2.2, –0.9) 26 30.8 (13.0, 48.5) 26 42.3 (23.3, 61.3)
CDAI 121 30.4 (13.4) 115 −15.2 (−17.6, –12.8) 119 8.4 (3.4, 13.4) 119 38.7 (29.9, 47.4)

CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate.

Nüßlein et al.

Nüßlein et al. BMC Musculoskeletal Disorders 2014 15:14   doi:10.1186/1471-2474-15-14

Open Data